SCHEMBL1437643

SCHEMBL1437643

Cc1cccc(C(=N)Nc2cc(Cl)ccc2C)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
GAA P10253 2/20 0.44
KDM4E B2RXH2 3/20 0.43
HTT P42858 3/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
NPC1 O15118 1/20 0.43
NPY1R P25929 1/20 0.43
NPY2R P49146 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
GRM5 P41594 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KMT2A Q03164 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437117 0.81 MAPT (0.52) MAPTGAAHTTLMNANPC1
SCHEMBL1437250 0.75 GRM5 (0.42) KDM4EPOLBNPC1RAB9ANPSR1
SCHEMBL1436924 0.75 GAA (0.50) MAPTGAAKDM4EHTTPOLB
SCHEMBL1437599 0.75 GAA (0.50) MAPTGAAKDM4EHTTPOLB
SCHEMBL9893687 0.74 GAA (0.47) MAPTGAAKDM4EHTTPOLB
SCHEMBL1437427 0.72 GAA (0.50) MAPTGAAKDM4EPOLBLMNA
SCHEMBL1437752 0.71 KCNMA1 (0.52) MAPTGAAHTTLMNARAB9A
SCHEMBL14516182 0.71 GAA (0.60) MAPTGAAKDM4EHTTPOLB
SCHEMBL1580850 0.70 P2RX7 (0.50) KDM4ENPC1RAB9ANPSR1GRM5
SCHEMBL18414338 0.70 P2RX7 (0.50) RAB9AGRM5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MAPT 582/4885GAA 2555/4885KDM4E 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.